Twist Bioscience Stock Forecast, Price & News

Twist Bioscience (NASDAQ:TWST) Frequently Asked Questions

Is Twist Bioscience a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Twist Bioscience stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TWST, but not buy additional shares or sell existing shares.
View analyst ratings for Twist Bioscience or view top-rated stocks.

What stocks does MarketBeat like better than Twist Bioscience?

Wall Street analysts have given Twist Bioscience a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Twist Bioscience wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Twist Bioscience's next earnings date?

Twist Bioscience is scheduled to release its next quarterly earnings announcement on Monday, November 22nd 2021.
View our earnings forecast for Twist Bioscience.

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Co. (NASDAQ:TWST) released its quarterly earnings data on Thursday, August, 5th. The company reported ($0.82) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.75) by $0.07. The business earned $35.02 million during the quarter, compared to analyst estimates of $32.43 million. Twist Bioscience had a negative net margin of 106.59% and a negative trailing twelve-month return on equity of 24.59%. The firm's quarterly revenue was up 65.1% on a year-over-year basis. During the same period last year, the company posted ($0.67) earnings per share.
View Twist Bioscience's earnings history.

How has Twist Bioscience's stock price been impacted by Coronavirus?

Twist Bioscience's stock was trading at $28.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TWST stock has increased by 297.6% and is now trading at $112.11.
View which stocks have been most impacted by COVID-19.

What guidance has Twist Bioscience issued on next quarter's earnings?

Twist Bioscience updated its FY 2021 earnings guidance on Friday, September, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $129 million-$132 million, compared to the consensus revenue estimate of $127.12 million.

What price target have analysts set for TWST?

6 brokers have issued 1-year target prices for Twist Bioscience's shares. Their forecasts range from $100.00 to $150.00. On average, they anticipate Twist Bioscience's share price to reach $118.00 in the next twelve months. This suggests a possible upside of 5.3% from the stock's current price.
View analysts' price targets for Twist Bioscience or view top-rated stocks among Wall Street analysts.

Who are Twist Bioscience's key executives?

Twist Bioscience's management team includes the following people:

• Emily Marine Leproust, Chairman, President & Chief Executive Officer
• Patrick Weiss, Chief Operating Officer (LinkedIn Profile)
• James M. Thorburn, Chief Financial Officer
• Siyuan Chen, Chief Technology Officer
• Aaron K. Sato, Chief Scientific Officer

What is Emily Leproust's approval rating as Twist Bioscience's CEO?

44 employees have rated Twist Bioscience CEO Emily Leproust on Glassdoor.com. Emily Leproust has an approval rating of 83% among Twist Bioscience's employees.

Who are some of Twist Bioscience's key competitors?

Some companies that are related to Twist Bioscience include Bio-Techne (TECH), Novavax (NVAX), Repligen (RGEN), Novozymes A/S (NVZMY), argenx (ARGX), QIAGEN (QGEN), Acceleron Pharma (XLRN), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Exelixis (EXEL), Beam Therapeutics (BEAM), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Halozyme Therapeutics (HALO) and Vir Biotechnology (VIR).
View all of TWST's competitors.

What other stocks do shareholders of Twist Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).

When did Twist Bioscience IPO?

(TWST) raised $75 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers.

What is Twist Bioscience's stock symbol?

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Who are Twist Bioscience's major shareholders?

Twist Bioscience's stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (10.34%), Vanguard Group Inc. (8.48%), BlackRock Inc. (7.88%), Sumitomo Mitsui Trust Holdings Inc. (5.17%), Nikko Asset Management Americas Inc. (5.16%) and Invesco Ltd. (3.91%). Company insiders that own Twist Bioscience stock include Bill Peck, Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess and William Banyai.
View institutional ownership trends for Twist Bioscience.

Which institutional investors are selling Twist Bioscience stock?

TWST stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, BlackRock Inc., Ikarian Capital LLC, Bank of New York Mellon Corp, FMR LLC, Jennison Associates LLC, Invesco Ltd., and Allianz Asset Management GmbH. Company insiders that have sold Twist Bioscience company stock in the last year include Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess, and William Banyai.
View insider buying and selling activity for Twist Bioscience or view top insider-selling stocks.

Which institutional investors are buying Twist Bioscience stock?

TWST stock was acquired by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Vanguard Group Inc., Marshall Wace LLP, Goldman Sachs Group Inc., Price T Rowe Associates Inc. MD, Macquarie Group Ltd., and State Street Corp.
View insider buying and selling activity for Twist Bioscience or or view top insider-buying stocks.

How do I buy shares of Twist Bioscience?

Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Twist Bioscience's stock price today?

One share of TWST stock can currently be purchased for approximately $112.11.

How much money does Twist Bioscience make?

Twist Bioscience has a market capitalization of $5.53 billion and generates $90.10 million in revenue each year. The company earns $-139,930,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis.

How many employees does Twist Bioscience have?

Twist Bioscience employs 525 workers across the globe.

What is Twist Bioscience's official website?

The official website for Twist Bioscience is www.twistbioscience.com.

Where are Twist Bioscience's headquarters?

Twist Bioscience is headquartered at 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080.

How can I contact Twist Bioscience?

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (800) 719-0671 or via email at [email protected].